SUPPLEMENTARY MATERIAL

Table S1. List of primers used to detect resistance genes, capsular types, toxin-antitoxin systems, incompatibility groups.

Primer	Sequence (5'-3')	Product size (bp)	mT[a]	Reference
β-lactamics				
bla$_{KPC}$	5' AACAAGGAATATCGTTGATG 3' 5' AGATGATTTTCAGAGCCTTA 3'	915	50	(1)
bla$_{OXA-48}$	5' TTGGTGGCATCGATTATCGG 3' 5' GAGCACTTCTTTTGTGATGGC 3'	743	50	(1)
bla$_{GES}$	5' GAAAAAGCAGCTGAGATCG 3' 5'CAACAACCCAATCTTTAGGA 3'	579	56	(2)
bla$_{CTX-M-1}$	5' CCCATGGTTAAAAAATCACTG 3' 5' CGTAGCCGGGCCGCCAACGTGA 3'	830	58	(3)
bla$_{CTX-M-2}$	5' TTAATGATGACTCAGAGCATT 3' 5' GATACCTCGCTCCATTTATTGC 3'	875	56	(4)
bla$_{CTX-M-g3}$	5' ACCTGATTAACTACAATCCCAT 3' 5' ACTTTCTGCCTTCTGCTCTGGC 3'	514	59	(5)
bla$_{CTX-M-g4}$	5' CTGGAGAAAAGCAGCGGAG 3' 5' GTAAGCTGACGCAACGTCTG 3'	473	61	(6)
bla$_{CTX-M-g25}$	5' CCGTCGGTGACAATTCTGGC 3' 5' AGAAAAAGCGTAAGGCGGGC 3'	862	60	(7)
bla$_{TEM}$	5' ATGAGTATTCAACATTTCCG 3' 5' CCAATGCTTAATCAGTGAGG 3'	858	57	(4)
bla$_{SHV}$	5' ATGATGAGCACCTTTAAAGTA 3' 5' ATTTCGCTCGGCCATGCTCGC 3'	623	56	(4)
bla$_{OXA-1}$	5' GGCACCAGATTCAACTTTCAAG 3' 5' GACCCCAAGTTTCCTGTAAGTTG 3'	546	58	(8)
bla$_{OXA-2}$	5' CCTGCATCGACATTCAAGATA 3' 5' CTCAACCCATCCTACCCACCA 3'	464	58	(9)
bla$_{PER-2}$	5' TGTGTTTTCACCGCTTCTGCTCTG 3' 5' AGCTCAAACTGATAAGCCGCTTG 3'	900	56	(4)
Quinolones				
qnrA	5' ATTTCTCACGCCAGGATTTG 3' 5' GATCGGCAAAGGTTAGGTCA 3'	516	57	(10)
qnrB	5' GATCGTGAAAGCCAGAAAGG 3' 5' ACGACGCCTGGTAGTTGTCC 3'	469	56	(10)
qnrC	5' GGGTTGTACATTTATTGAATC 3' 5' CACCTACCCATTTATTTTCA 3'	307	54	(11)
qnrD	5' CGAGATCAATTTACGGGGAATA 3' 5' AACAAGCTGAAGCGCCTG 3'	580	55	(12)
qnrS	5' ACGACATTCGTCAACCTGCAA 3' 5' TAAATTGGCACCCTGTAGGC 3'	417	57	(10)
qnrVC	5' ATGGAAAAATCAAAGCAATT 5' TTAGTCAGGAACAATGATTA	656	50	(13)
qepA	5' AACTGCTTGAGCCCGTAGAT 3' 5' GTCTACGCCATGGACCTCAC 3'	595	60	(11)
Aminoglycosides				
Aac(6')Ib	5' TTGCGATGCTCTATGAGTGGCTA 3' 5' CTCGAATGCCTGGCGTGTTT 3'	481	59	(11)
armA	5' ATTCTGCCTATCCTAATTGG 3' 5' ACCTATACTTTATCGTCGTC 3'	315	55	(1)
rmtA	5' CTAGCGTCCATCCTTTCCTC 3' 5' TTGCTTCCATGCCCTTGCC 3'	635	55	(1)
rmtB	5' GCTTTCTGCGGGCGATGTAA 3'	173	55	(1)

	5’ ATGCAATGCCGCGCTCGTAT 3’			
rmtC	5’ CGAAGAAGTAACAGCCAAA 3’	711	55	(1)
	5’ ATCCCAACATCTCTCCCACT 3’			
rmtD	5’ CGGCACGCGATTGGGAAGC 3’	401	55	(1)
	5’ CGGAAACGATGCGACGAT 3’			
npmA	5’ CTCAAAGGAACAAAGACGG 3’	641	58	(1)
	5’ GAAACATGGCCAGAAACTC 3’			
Fosfomycin				
fosA	5’ ATCTGTGGGTCTGCCTGTCGT 3’	271	54	(14)
	5’ ATGCCCGCATAGGGCTTCT 3’			
fosA3	5’ TGAATCATCTGACGCTGG 3’	404	49	(15)
	5’ TCAATCAAAAAAGACCATC 3’			
Colistin				
mcr-1	5’ CGGTCAGTCCGTTTGTTC 3’	310	49	(16)
	5’ CTTGGTCGGTCTGTAGGG 3’			
mcr-2	5’ TGGTACAGCCCCTTTATT 3’	1626	52	(17)
	5’ GCTTGAGATTGGGTTATGA 3’			
mcr-3	5’ TTGGCACTGTATTTTGCATTT 3’	542	53	(18)
	5’ TTAACGAAATTGGCTGGAACA 3’			
mgrB	5’ AAGGCGTTCATTCTACCACC 3’	1500	54	(19)
	5’ TTAAGAAGGCCGTGCTATCC 3’			
Capsular type				
wzi	5’ GTGCCGCGAGCGCTTTCTATCTTGGTATTCC 3’	580	59	(20)
	5’ GAGAGCCACTGGTTCCAGAA[CorT]TT[CorG]ACCGC 3’			
Toxin-antitoxin systems				
pemKI	5’ AACGAGAATGGCTGGATGC 3’	232	58	(21)
	5’ CCAACGACACCGCAAAGC 3’			
ccdAB	5’ AGGAAGGGATGGCTGAGGT 3’	230	58	(21)
	5’ GGTAAAGTTCACGGGAGAC 3’			
relE	5’ AAAAACCCGATGGCGACAG 3’	370	61	(21)
	5’ TGATAGACCAGGCGAAAAC 3’			
parDE	5’ ACGGACCAGCAGCACCAG 3’	534	62	(21)
	5’ AGCCCTTGAGCCTGTCGG 3’			
vagCD	5’ GGGACCTGGATTTTGATGG 3’	210	57	(21)
	5’ GAGCAGATGTTGGTGTCG 3’			
hok-sok	5’ AGATAGCCCCGTAGTAAGTT 3’	203	58	(21)
	5’ GATTTTCGTGTCAGATAAGTG 3’			
pndAC	5’ CCTCACCATCCAGACAAAA 3’	140	56	(21)
	5’ TCAATCAACCAGGGCTCT 3’			
srnBC	5’ ACTGATTGTAGCCTCTTCTTT 3’	171	58	(21)
	5’ CACCACTGTATTTCCCCTGT 3’			
Incompatibility Groups				
HI1	5’ GGAGCGATGGATTACTTCAGTAC 3’	471	62	(22)
	5’ TGCCGTTTCACCTCGTGAGTA 3’			
HI2	5’ TTTCTCCTGAGTCACCTGTTAACAC 3’	644	62	(22)
	5’ GGCTCACTACCGTTGTCATCCT 3’			
I1	5’ CGAAAGCCGGACGGCAGAA 3’	139	62	(22)
	5’ TCGTCGTTCCGCCAAGTTCGT 3’			
X	5’ AACCTTAGAGGCTATTTAAGTTGCTGAT 3’	376	62	(22)
	5’ TGAGAGTCAATTTTTATCTCATGTTTTAGC 3’			
L/M	5’ GGATGAAAACTATCAGCATCTGAAG 3’	785	62	(22)
	5’ CTGCAGGGGCGATTCTTTAGG 3’			
N	5’ GTCTAACGAGCTTACCGAAG 3’	559	62	(22)
	5’ GTTTCAACTCTGCCAAGTTC 3’			
FIA	5’ CCATGCTGGTTCTAGAGAAGGTG 3’	462	62	(22)
	5’ GTATATCCTTACTGGCTTCCGCAG 3’			
FIB	5’ GGAGTTCTGACACACGATTTTCTG 3’	702	62	(22)
	5’ CTCCCGTCGCTTCAGGGCATT 3’			
W	5’ CCTAAGAACAACAAAGCCCCCG 3’	242	62	(22)

	5’ GGTGCGCGGCATAGAACCGT 3’			
Y	5’ AATTCAAACAACACTGTGCAGCCTG 3’	765	62	(22)
	5’ GCGAGAATGGACGATTACAAAACTTT 3’			
P	5’ CTATGGCCCTGCAAACGCGCCAGAAA 3’	534	62	(22)
	5’ TCACGCGCCAGGGCGCAGCC 3’			
FIC	5’ GTGAACTGGCAGATGAGGAAGG 3’	262	62	(22)
	5’ TTCTCCTCGTCGCCAAACTAGAT 3’			
A/C	5’ GAGAACCAAAGACAAAGACCTGGA 3’	465	62	(22)
	5’ ACGACAAACCTGAATTGCCTCCTT 3’			
T	5’ TTGGCCTGTTTGTGCCTAAACCAT 3’	750	62	(22)
	5’ CGTTGATTACACTTAGCTTTGGAC 3’			
FIIs	5’ CTGTCGTAAGCTGATGGC 3’	270	62	(22)
	5’ CTCTGCCACAAACTTCAGC 3’			
F	5’ TGATCGTTTAAGGAATTTTG 3’	270	56	(22)
	5’ GAAGATCAGTCACACCATCC 3’			
K	5’ GCGGTCCGGAAAGCCAGAAAAC 3’	160	56	(22)
	5’ TCTTTCACGAGCCCGCCAAA 3’			
B/O	5’ GCGGTCCGGAAAGCCAGAAAAC 3’	160	56	(22)
	5’ TCTGCGTTCCGCCAAGTTCGA 3’			

[a] melting temperature

References

1. Bado I, Papa R, Delgado JF, Gaudio M, Gutiérrez C, Cordeiro NF, García-Fulgueiras V, Araújo L, Seija V, Medina JC, Rieppi G, González-Zorn B, Vignoli R. Molecular characterization of carbapenem-resistant Acinetobacter baumannii in the ICU of Uruguay’s University Hospital identifies the first rmtC gene in the species. Micr Drug Resist. 2018; 24:1012-1019.

2. Pasterán F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, Vázquez M, Procopio A, Tokumoto M, Cagnoni V. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother. 2006; 50:3222–3224.

3. Cordeiro NF, Robino L, Medina J, Seija V, Bado I, Garcia V, Berro M, Pontet J, Lopez L, Bazet C, Rieppi G, Gutkind G, Ayala JA, Vignoli R. Ciprofloxacin-resistant enterobacteria harboring the aac(6’)-Ib-cr variant isolated from feces of inpatients in an intensive care unit in Uruguay. Antimicrob Agents Chemother 2008; 52:806–807.

4. Vignoli R, Calvelo E, Cordeiro NF, Lucero R, Ingold E, Quintana A, Del Monte A, Schelotto F. Association of broad-spectrum antibiotic use with faecal carriage of oxyiminocephalosporin-resistant enterobacteriaceae in an intensive care unit. J Hosp Infect. 2006; 63:306–315.

5. Lewis 2nd JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother. 2007; 51:4015–4021.

6. Abdelghani SMM, Moland SM, Black JA, Hanson ND, Goering RV, Thomson KS, et al. First Report of CTX-M-14 -Producing Clinical Isolates of *Salmonella* Serovar Typhimurium from Egypt. *Journal of Infection in Developing Countries.* 2010. 4:058–060.

7. Lopes ACS, Leal-Veras D, Lima AMS, De Cassia Andrade Melo R, Ayala J. “*bla*CTX-M-2 and *bla*CTX-M-28 Extended-Spectrum β-Lactamase Genes and Class 1 Integrons in Clinical Isolates of *Klebsiella pneumoniae* from Brazil.” *Mem* 2010. 105:163–67.

8. Loncehl Magoue C, Melin P, Gangoue-Pieboji J, Okomo Assoumou M-C, Boreux R, De Mol P. Prevalence and spread of extended spectrum beta-lactamase-producing Enterobacteriaceae in Ngaoundere, Cameroon. Clin Microbiol Infect. 2013; 19:E416–E420.

9. Vignoli R, Cordeiro NF, Seija V, Schelotto F, Radice M, Ayala J, et al. 2006. “Genetic environment of CTX-M-2 in *Klebsiella pneumoniae* isolates from hospitalized patients in Uruguay.” *Rev Argent Microbiol.* 2006; 38:84–88.

10. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. Qnr Prevalence in Ceftazidime-Resistant *Enterobacteriaceae* Isolates from the United States. *Antimicrobial Agents and Chemotherapy.* 2006. 50:2872–74.

11. Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. Prevalence of Plasmid-Mediated Quinolone Resistance Determinants over a 9-Year Period. *Antimicrob Agents Chemother* 2009. 53: 639–45.

12. Cavaco LM, Hasman H, Xia S, Aarestrup FM. *qnrD*, a Novel Gene Conferring Transferable Quinolone Resistance in *Salmonella enterica* Serovar Kentucky and Bovismorbificans Strains of Human Origin. *Antimicrob Agents Chemother* 2009; 53:603–8.

13. Liu M, Wong MHY, Chen S. Molecular characterisation of a multidrug resistance conjugative plasmid from Vibrio parahaemolyticus. Int J Antimicrob Agents 2013; 42:575–9.

14. Hou J, Huang X, Deng Y, He L, Yang T, Zeng Z, Chen Z, Liu JH. Dissemination of the Fosfomycin Resistance Gene *fosA3* with CTX-M Beta-Lactamase Genes and *rmtB* Carried on IncFII Plasmids among *Escherichia coli* Isolates from Pets in China. Antimicrobl Agents Chemother. 2012; 2135–2138.

15. Nakamura G, Wachino J, Sato N, Kimura K, Yamada K, Jin W, Shibayama K, Yagi T, Kawamura K, Arakawa Y. Practical Agar-Based Disk Potentiation Test for Detection of Fosfomycin-Nonsusceptible *Escherichia coli* Clinical Isolates Producing Glutathione *S*-Transferases. Journal of Clinical Microbiology. 2014. 52:3175–3179.

16. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu L-F, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu J-H, Shen J. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016. 16:161–168.

17. Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P, Goossens H, Malhotra-Kumar S. Identification of a novel plasmid-mediated colistin resistance gene, *mcr-2*, in *Escherichia coli*, Belgium. Euro Surveill. 2016; 21:1-6.

18. Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z, Zhang R, Walsh TR, Shen J, Wang Y. Novel Plasmid-Mediated Colistin Resistance Gene *mcr-3* in *Escherichia coli.* mBio. 2017; 8:1-6.

19. Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F, Conte V, Tryfinopoulou K, the COLGRIT Study Group, Vatopoulos A, Rossolinia GM. MgrB Inactivation Is a Common Mechanism of Colistin resistance in KPC-Producing *Klebsiella pneumoniae* of Clinical Origin. Antimicrob Agents Chemother. 2014; 58:5696–5703.

20. Brisse S, Passet V, Björk Haugaard A, Babosan A, Kassis-Chikhani N, Struve C, Decrée D. *wzi* Gene Sequencing, a Rapid Method for Determination of Capsular Type for *Klebsiella* Strains. Journal of Clinical Microbiology 2013; 51:4073–4078.

21. Mnif B, Vimont S, Boyd A, Bourit A, Picard B, Branger C, et al. Molecular Characterization of Addiction Systems of Plasmids Encoding Extended-Spectrum Beta-Lactamases in *Escherichia coli*. *J Antimicrob Chemother*. 2010. 65:1599–1603.

22. Carattoli A, Bertini A, Vila L, Falbo V, Hopkins KL, Threlfall EJ. Identification of Plasmids by PCR-Based Replicon Typing. *J Microbiol Methods*. 2005. 63: 219–28.